Viridian Therapeutics, Inc. or MiMedx Group, Inc.: Who Leads in Yearly Revenue?

MiMedx vs. Viridian: A Decade of Revenue Dominance

__timestampMiMedx Group, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 20141182230004320000
Thursday, January 1, 20151872960002538000
Friday, January 1, 20162450150003337000
Sunday, January 1, 20173211390004003000
Monday, January 1, 20183591110008386000
Tuesday, January 1, 20192992550004461000
Wednesday, January 1, 20202482340001050000
Friday, January 1, 20212586150002963000
Saturday, January 1, 20222678410001772000
Sunday, January 1, 2023321477000314000
Loading chart...

Unleashing the power of data

A Tale of Two Companies: Revenue Trends from 2014 to 2023

In the competitive landscape of biotechnology and medical solutions, MiMedx Group, Inc. and Viridian Therapeutics, Inc. have charted distinct paths over the past decade. From 2014 to 2023, MiMedx Group consistently outperformed Viridian in annual revenue, showcasing a robust growth trajectory. By 2018, MiMedx's revenue peaked at approximately 360 million, marking a 200% increase from 2014. In contrast, Viridian's revenue, while growing, remained modest, peaking at around 8 million in 2018 before declining.

The data reveals MiMedx's resilience and market adaptability, maintaining an average annual revenue of 263 million, despite fluctuations. Meanwhile, Viridian's revenue trajectory highlights the challenges faced by smaller biotech firms in scaling operations. As the industry evolves, these trends underscore the importance of strategic innovation and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025